Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Now I'm confused. I thought there was an HER2 phase 1 running somewhere? If not, then what "data" did they look at, as per the pr about putting HER2 on hold?
Your exactly correct Huskercatman! Seems the canine trials are going great yet we have no human trials to date. Yet some people here would want you to believe our HER2 trials haven't been successful enough to warrant further trials? What? Lombardo is conserving cash at this time .. We're not abandoning our HER2 trials all together we're just not going to spend money starting a new trial! In fact we have fast track designation .
I guess our HER2 canine trials aren't good enough to pursue them in human trials? I thought our PETX trials were going super? Seems the dogs are surviving way past SOC treatments so why are we not good enough for pursuing HER2 in human trials?
spread the word. I did
Very cool, thanks gold007
Blue you did what you liked/loved now this ADXS better ramp-up so you can pay someone to make it like it was or even better.BOL to us
I am waiting it out as well
GLTARL
Ruined. The town gave the big trucks that pick up the landscape garbage to Fema,and they did`nt clear it away for over 4 weeks,,so my lawn is totally dead where the garbage was sitting. Need Adxs to go to 50 for me to even consider re doing any of the damage. I should`ve never did an elaborate landscape in a hurricane state.
That my friend is the "STOCK MARKET" for every buyer there is a seller and vice versa. So how is the property after the ravage?
I was commenting on your theory that Dan was a "mole" for Adage. Try reading it again.
I’m buying some of them:)
I can understand your argument.
Let us see how it works out.
I am not selling either and am willing to wait it out.
raja -
So why does BP not go ahead and buy ADXS...?
Maybe under DOC it wasn't for sale and maybe now it is and deals take time. Given we have multiple partners the due diligence period is going to take some time. Any potential buyer would need to get intimate with all the other partnership and I bet it gets tricky. Let's say AZ is looking to buy us outright. Before they open their wallets they will want to see what is their exposure with BMY, Merck, Amgen, etc. It's not going to be easy to share deals with other competitors. If you were BMY, you wouldn't want AZ looking under your sheets.
This will take time. Because of this complexity (all the deals) I believe that is why the BOD handed it over to Lombardo to sort out and to get it done.
He needs time and thus the shorts opportunity to drive share price lower. Make money, cover, then go long. The shorts (smart money) will profit from both directions.
I'm holding and will not sell. Selling now is like being an accessary to a crime. Let the shorts work to cover. Im not going to make it easy on them by selling. I would have sold long ago if I didn't believe in the ultimate outcome.
Have a good evening.
attilathehunt,
You know that it is worth a lot more than $15 - and I do not disagree.
So why does BP not go ahead and buy ADXS, if folks like you and me know that is worth more than $15? Certainly they are more knowledgeable than any of us here.
raja.... good question. Evidently, based on the clinical results that we DO have from GOG, head and neck cancer and anal cancer (even though the sample sizes were quite low) .... the Reward VS the Risk is not quite there yet according to potential BP suitors. I find that baffling in today's Biotech landscape when BPs are paying a lot of money for small Baby Biotechs that have NO products as far along as what ADXS has currently. It's a real head scratcher, I must admit. Maybe it will take EU Approval to get there. Unfortunately, that is probably going to be at least a year away as slow as ADXS is. They just continue to hobble along at a snail's pace with ZERO sense of urgency. It's very frustrating.
Plus they timed it to break the stock down below the 5.20,and cause other to sell,via stop losses,etc.
The silly thing is that every share sold is bought,and the difference between a buy and a sale is never more than a penny so when posters talk about all the shares being sold,someone`s buying them all. When there`s more buyers than sellers the share price rises and vice versa,but shares sold are always bought by someone.
Bourbon that sale by Adage was likely to cover a short position (i.e., selling the shares they bought at $19 for a tax loss to offset the gain from covering a short position put on on the $20s).
all big blocks should be considered as a buy, otherwise the price would be sharply dropped, IMO.
based on nothing? didn't Adage file a sale document with the SEC?
and Adage was about as long as you can get, they are practically insiders becuase their long position was so big. did you think at all before replying to my original post?
raja -What is holding them back?
No one is holding back because what you suggest in unrealistic.
I don't know a fair price but I do know this is worth a lot more than $15.
The Adage conspiracy with Dan is a fantasy based on nothing. And I'm talking about long tutes, not short Hedgies with their robots.
If Advaxis' formulations are cheaper than the alternatives and more effective then the only limits to market penetration are production capacity and distribution. we know that production is readily scaleable and we can assume that lenders will be willing to finance additional plant if the market warrants.
PLenty of evidence here that Tutes get very emotional. Seems Adage sold off a big chunk when their mole, er CEO, got canned. And someone has had a hard-on for this stock since it started plummeting at $30.
Hammys would be the bomb but right now Washingtons would do
Three who sold under 10? Out of how many? 40? Tutes sell for various reasons that have nothing to do with them believing that a stock is fairly valued at the current price. By your own account, the average analyst estimate is $23 a share. Which is not even a full value estimate, it's a price target. Tutes have analysts. You think any of them place a value on ADXS of $15 a share? I seriously doubt it. Adage bought shares at 19 2 1/2 years ago, and the company is much further along now. You seem to think that tutes get emotional and desperate, like the retail here. They don't.
LOL....you don't understand what I wrote. Go read it, it still pinned.
I said 10% likelihood of success, of that, 50% market share.
That's 5% in my book.
Very conservative.
And we have absolutely NOTHING in common with DNDN. Completely different tech that only added 3-4 months to life at best at an astronomical cost.
SELL THIS AND PUT IT OF ITS MISERY ADXS
Open Question
Why is BP not making any effort to grab Advaxis NOW if everyone here believes that this company is going to be worth billions in a matter of 18 to 24 months? We would have read about some rumor that some BP is going after this company.
Heck! even a 200% premium from the current pps would be a steal for them, given the huge potential . It is not that they cannot afford to pay a few hundred million right now. They can recover their investment in a couple of qtrs. once they have ADXS making them money.
Obviously BP knows more about ADXS potential than anyone here does - or does anyone here challenge that argument too?
What is holding them back?
You are making a generalization about all tutes knowing the value is much more than $15, but I just gave you an example of three who sold under $10.
Well, I disagree. The tutes know full well that the stock is worth many times the current share price. They have actual analysts who figure that out, as opposed to retail thinking "oh no, the stock is down, how can I get out of this regardless of price?" Any tute with a clue who invests in clinical biotech understands the manipulation game and the timelines. They also know that management may have made mistakes but nothing that justifies this share price, or even $15.
Not necessarily - since tutes like Broadfin, Pictet and T Rowe Price sold out for under $10, there will be plenty willing to sell out for $15, especially given low investor confidence that ADXS management can do any better.
I doubt they would need to fight off a buyout offer. The tutes would reject $15, imo.
Or they are legitimate trades at the market in a dark pool. The pools have much larger quotes, all tutes.
It would make more sense to inquire about Avastin's market share, as opposed to DNDN's flawed product.
WRONG! "If Amgen or anyone else offered to buy this company for $15 a share they would be laughed out of the Advaxis board room."
WRONG! the BOD would be petrified because they could not be sure of surviving such an offer. They would be speed dialing a big investment bank to prepare a defense, and calling every white knight they could think of. Quite frankly, I am not sure they could fight off a $15 offer.
I'm sure their software labels it as a buy or sell, but unless they are doing that for each individual trade it is probably essentially a guess. The computerized trading by the mm's move very quickly so it is very difficult to tell what trade was at the bid and what was at the ask. Or in between. They can also disguise the nature of the trades fairly easily, such as by lowering the ask to the bid? Is that a sell or a buy? Alot of trades fall into a grey area.
Another 100K block. These are obviously prearranged. Somebody is moving around shares. No way to really know what it means (yet).
Mpreorder, why don't you ask some of the former executives of Dendreon if your assumption that all ADXS constructs will get 50% of the market share of all cancer cases for our targeted caners is a conservative assumption.
Well why do they have the “B” over the green bar and “S” over the red indicator. It’s at the top not saying it’s correct but that is what they’re indicating.
You and me both, Gantor. I hope they got millions of shares and made alot of money. Just get it the "f" over with already.
The same thing happened yesterday for 147k.
"IHub has it listed as a sell." What do you mean? On the chart the bar is red? That doesn't mean anything. The only way to know with any reasonable certainty is to see it live on Level II. The next best is to compare it to the surrounding trades after-the-fact. It is particularly hard to figure out when a large trade does not come in below or above the market.
At this point I am just hoping the entities that drove this into the ground declare mission accomplished, deposit their $10s of Millions in profits in the bank, and are now looking to turn the car around and start driving North to profit in the other direction.
I'll happily ride along as the bug on the windshield.
Hope it’s a buy so I’ll take Fidelity’s word anyway. Agree amazing how the price doesn’t move because of these prearranged buy/sells. Hope it ends soon
Fidelity shows it as a buy. Either way 100+K should result in a bigger move (either way) if it was a normal market trade. During the attack I watched them take it down .60 cents on less than 75K shares.
Followers
|
396
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
108192
|
Created
|
12/05/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |